Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Dutta
Usha
U
Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. ushadutta@gmail.com
Udawat
Harsh
H
Noor
Mohd Talha
MT
Sidhu
Gurbakhshish Singh
GS
Kochhar
Rakesh
R
Vaiphei
Kim
K
Singh
Kartar
K
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D007161:Immunoproliferative Small Intestinal Disease / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D014011:Tinidazole / Q000627:therapeutic use; D055815:Young Adult
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D014011:Tinidazole; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole; D004318:Doxycycline